Abstract
The pharmacokinetics and tolerance of acyclovir administered intravenously in single doses of 2.5, 5.0, 10.0, and 15.0 mg/kg were studied in 13 volunteers. The mean concentrations (+/- standard deviations) at the end of infusion as measured by radioimmunoassay were 4.52 +/0 0.31, 8.28 +/- 2.61, 14.6 +/- 2.30, and 22.7 +/- 10.4 microgram/ml, respectively. Drug elimination during and after the infusion of acyclovir was well described by a two-compartment open model. The mean terminal plasma half-life for each of the groups was 2.85, 2.80, 3.30, and 2.38 h, respectively. Within 72 h after the start of the infusion, 70% of the administered drug was recovered in the urine as unchanged acyclovir. The renal clearance of acyclovir accounted for about 77% of the total clearance and was about threefold greater than the creatinine clearance. This confirms that acyclovir is eliminated predominantly by the kidneys in patients with normal renal function and suggests that renal secretion and glomerular filtration may both be involved. The only adverse effect found by clinical and laboratory monitoring was irritation at he intravenous site after extravasation (in two cases), which resolved without significant sequelae.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brigden D., Bye A., Fowle A. S., Rogers H. Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother. 1981 Apr;7(4):399–404. doi: 10.1093/jac/7.4.399. [DOI] [PubMed] [Google Scholar]
- Collins P., Bauer D. J. The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent. J Antimicrob Chemother. 1979 Jul;5(4):431–436. doi: 10.1093/jac/5.4.431. [DOI] [PubMed] [Google Scholar]
- Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gehan E. A., George S. L. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970 Aug;54(4):225–235. [PubMed] [Google Scholar]
- Mawer G. E., Lucas S. B., Knowles B. R., Stirland R. M. Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet. 1972 Jan 1;1(7740):12–15. doi: 10.1016/s0140-6736(72)90005-0. [DOI] [PubMed] [Google Scholar]
- Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
- Spector S. A., Connor J. D., Hintz M., Quinn R. P., Blum M. R., Keeney R. E. Single-dose pharmacokinetics of acyclovir. Antimicrob Agents Chemother. 1981 Apr;19(4):608–612. doi: 10.1128/aac.19.4.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Miranda P., Good S. S., Laskin O. L., Krasny H. C., Connor J. D., Lietman P. S. Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther. 1981 Nov;30(5):662–672. doi: 10.1038/clpt.1981.218. [DOI] [PubMed] [Google Scholar]
- de Miranda P., Whitley R. J., Blum M. R., Keeney R. E., Barton N., Cocchetto D. M., Good S., Hemstreet G. P., 3rd, Kirk L. E., Page D. A. Acyclovir kinetics after intravenous infusion. Clin Pharmacol Ther. 1979 Dec;26(6):718–728. doi: 10.1002/cpt1979266718. [DOI] [PubMed] [Google Scholar]